Splash Begins Expansion Phase of SPL-108 Trial for Ovarian Cancer Patients

Splash Begins Expansion Phase of SPL-108 Trial for Ovarian Cancer Patients
Splash Pharmaceuticals has successfully completed the safety stage of its Phase 1 trial testing a combination of SPL-108 and chemotherapy in platinum-resistant ovarian cancer patients, the company announced in a press release. Taking place at Rutgers Cancer Institute of New Jersey, the open-label trial (NCT03078400) is now recruiting participants into its dose escalation phase. “The target, mechanism of

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *